CATALYSTYahoo Finance • 12h ago
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?Yahoo Finance report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
Why GKOS Stock dropped -2.01% Today — RQD Quant Desk Flash
$237.60 -2.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $236.29
Glaukos Corporation (GKOS) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $14.35B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GKOS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GKOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Glaukos Corporation (NYSE: GKOS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $237.60 (-2.01% 1D, market cap $14.35B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GKOS ranks #193 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GKOS compare to SOLV and PEN in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), GKOS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -13.7%. By comparison, SOLV (Solventum Corporation) holds a D grade (45/100 RQD, P/E 9.1x, ROIC 18.7%, cap $14.22B) and PEN (Penumbra Inc.) posts a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.68B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while SOLV leads on capital efficiency (18.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GKOS?
▼
Per GKOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001192448), Glaukos Corporation generated $507.4M in revenue (+32.3% YoY), -$187.7M in net income, and -$22.5M in free cash flow against $893.5M in total assets and $106.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $236.29 (-0.55%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GKOS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY GKOS SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (33% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$165.50+4.8% Next Q
50
Q2 (-2Q)Grade C-$173.43+4.5% Next Q
53
Q3 (-1Q)Grade C$181.17+31.1% Next Q
55
CurrentGrade D+$237.60+0% Hist 90D α
58
Trajectory: C- (50) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the GKOS Bull Thesis Could Fail
Even with a 58/100 (D+) score, GKOS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($175.58) or 200D SMA ($142.70) invalidates the momentum regime and cuts Target Base ($237.60) toward Bear Floor ($185.33).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GKOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GKOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GKOS Stock dropped -2.01% Today — RQD Quant Desk Flash
Glaukos Corporation (GKOS) dropped -2.01% to $237.60, trading at 93% of its 52-week range ($80.9 – $248.75). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 93% of its 52-week range ($80.9 – $248.75) with RSI-14 at 83.5 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $237.60 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 55.7% gross margin and $0 annual free cash flow.
Live GKOS Headlines & Catalysts
MARKET WIRESeeking Alpha • 15h ago
Glaukos stock slips after insider selling (GKOS:NYSE)Seeking Alpha report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 18h ago
Glaukos Corporation Stock 12‑Month Price Target Raised to $235.46, Implies 30% UpsideTradingView report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 21h ago
Glaukos (NYSE:GKOS) Stock Forecast & Analyst PredictionsSimply Wall St report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A live webcast on Glaukos's third-quarter results is set for Oct. 28 at 1:30 p.m. PT.Stock Titan report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Earnings Flash (GKOS) Glaukos Corporation Posts Q3 Adjusted EPS $0.47 per Share, vs. FactSet Est of $-0.10marketscreener.com report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
CATALYSTKalkine • 1d ago
Top 5 Stocks for October 29 Pre-Market: Earnings Reaction Gainers Led by Glaukos Corporation (NYSE:GKOS) at 15.75%Kalkine report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Why Glaukos (GKOS) Stock Is Up TodayQuiver Quantitative report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 15h ago
Can CAH's Specialty Strength Offset Medical Distribution Challenges in Q1?Can Cardinal Health's pharmaceutical demand and specialty growth drive Q1 earnings higher despite medical distribution cost pressures and recent stock weakness?
MARKET WIREYahoo • 16h ago
iShares Russell 2000 (IWM) Adds Jackson Financial, Trims Glaukos on ThursdayThe fund sold $292.1 million more than it bought, with 1,876 positions decreased and one increased.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GKOS)
- ✓Walkthrough of GKOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GKOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +74.90%📐 HORIZONTAL RANGE
2026-11-02O $181.4H $242.5L $181.4C $237.6VOL 5.42M
RES: $250.5SUP: $146.6SMA50: $175.6SMA200: $142.7
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GKOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
26.2%/yr Implied 5Y Growth
vs. +32.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GKOS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GKOS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GKOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GKOS)
Health Care Rank #193 of 1016
⚔️ SOLV vs GKOS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GKOS vs. SOLV, PEN, BAX, GMED)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Glaukos Corporation (GKOS) ranks #193 by composite RQD confidence (58/100, grade D+) and #82 by equity capitalization ($14.35B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while SOLV leads on capital efficiency and profitability with 18.7% ROIC and 53.5% gross margin. GMED currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with GKOS at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GKOS
ACTIVE
Glaukos Corporation | D+ | 58/100 | — | 55.7% | -13.7% | -2.01% | $14.35B | Benchmark Subject |
| SOLV Solventum Corporation | D | 45/100 | 9.1x | 53.5% | 18.7% | -2.67% | $14.22B | /solv-vs-gkos → |
| PEN Penumbra Inc. | D+ | 57/100 | 71.4x | 67.1% | 10.6% | -0.94% | $12.68B | /pen-vs-gkos → |
| BAX Baxter International Inc. | D | 51/100 | — | 30.1% | -2.4% | -2.13% | $12.15B | /bax-vs-gkos → |
| GMED Globus Medical Inc. | B | 72/100 | 20.7x | 67.4% | 8.7% | -5.86% | $11.13B | /gmed-vs-gkos → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001192448In its most recent audited fiscal period (FY2025, filed 2025-12-31), Glaukos Corporation (GKOS) reported GAAP revenue of $507.4M (+32.3% vs. FY2024 revenue of $383.5M , and +61.2% cumulative change since FY2023) , GAAP net income of -$187.7M, operating cash flow of -$14.8M, and free cash flow of -$22.5M (+66.8% YoY). On the balance sheet, GKOS closed FY2025 with $893.5M in total assets against $106.8M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $507.4M | -$187.7M | -$14.8M | -$22.5M | $893.5M | $106.8M |
| FY2024 (FY) | 2024-12-31 | $383.5M | -$146.4M | -$61.3M | -$67.6M | $974.8M | $93.5M |
| FY2023 (FY) | 2023-12-31 | $314.7M | -$134.7M | -$57.8M | -$71.9M | $7.89B | $1.85B |
3. GKOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GKOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Glaukos Corporation (NYSE: GKOS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $237.60 (-2.01% 1D, market cap $14.35B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GKOS ranks #193 in composite RQD confidence.
How does GKOS compare to SOLV and PEN in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), GKOS carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -13.7%. By comparison, SOLV (Solventum Corporation) holds a D grade (45/100 RQD, P/E 9.1x, ROIC 18.7%, cap $14.22B) and PEN (Penumbra Inc.) posts a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.68B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while SOLV leads on capital efficiency (18.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GKOS?
Per GKOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001192448), Glaukos Corporation generated $507.4M in revenue (+32.3% YoY), -$187.7M in net income, and -$22.5M in free cash flow against $893.5M in total assets and $106.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GKOS trading relative to its 50-day, 200-day, and 52-week technical levels?
GKOS last traded at $237.60 (-2.01% on volume of 2,074,459 shares), positioning the stock +35.32% above its 50-day simple moving average ($175.58) and +66.50% above its 200-day simple moving average ($142.70). Across its 52-week range of $80.90 to $248.75, GKOS sits at the 93.4% percentile with a 14-day RSI of 83.5 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($207.90 to $267.30).
GKOS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GKOS stock moving today?
Why GKOS Stock dropped -2.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 58/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
GKOS — Glaukos Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:14:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, GKOS scores 58 out of 100, grading D+ with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine (10 / 20): Per the RQD rating, this pillar reflects ROIC of -13.7% and an FCF yield of -0.16%. For an investor, this is the weakest signal: the business is not currently generating returns on invested capital or free cash flow to support its valuation from operations.
- Whale 13F Flow (19 / 20): This is the strongest pillar, reflecting institutional accumulation and options positioning. For an investor, this indicates large holders have been building positions, which can support price momentum, though it does not by itself validate the fundamentals.
- Insider Conviction (5 / 20): Per the RQD rating, this pillar reflects a cluster of SEC Form 4 and Congressional PTR flow scored low. Recent news also references insider selling (see Catalysts), so the insider signal is a weak support for the thesis.
- Macro Regime Fit (10 / 20): Per the RQD rating, beta of 1.04 and sector sensitivity place the stock near market-level volatility with limited defensive offset.
- Forensic Balance Sheet (14 / 20): Per the RQD rating, Altman Z 26, Piotroski F 5/9, and Debt/Equity 0.15 indicate a comparatively sound balance sheet relative to its earnings profile.
Taken together, the upside drivers are institutional accumulation and a balance sheet with low leverage. The valuation tradeoff is significant: the stock trades at a forward P/E of 34 while reporting negative trailing EPS and negative operating margin, so price is leaning on forward expectations rather than current cash generation. The weak cash-engine pillar is the central caution a prospective investor should weigh against the strong flow signals.
Business
Glaukos Corporation (GKOS) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry, per the profile. The source data does not itemize its products, customers, or revenue model beyond sector classification and reported revenue. Per the SEC financials, FY 2025 revenue was $507.4M, indicating a revenue-generating medical instruments business. Not available in source data for additional detail on product lines or customer segments.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $507.4M | $-199.6M | $-187.7M | N/A | $-22.5M | $90.8M | $106.8M |
| FY 2024 | $383.5M | $-122.4M | $-146.4M | N/A | $-67.6M | $169.6M | $93.5M |
| FY 2023 | $314.7M | $-128.7M | $-134.7M | N/A | $-71.9M | N/A | $1847.4M |
Per the SEC financials, revenue grew from $314.7M in FY 2023 to $507.4M in FY 2025, while operating and net losses persisted in each period. Per the market data, gross margin is 55.7%, operating margin is -39.3%, and net margin is -37%, with ROIC at -13.7%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Per the RQD rating, Debt/Equity is 0.15, and per the SEC financials, cash declined from $169.6M in FY 2024 to $90.8M in FY 2025.
Open Questions
- What is the trailing P/E, given that the market data shows it as not available while EPS (TTM) is -3.17?
- How do the Q3 adjusted EPS figure of $0.47 and the trailing GAAP EPS of -3.17 reconcile, and what drove the gap versus the FactSet estimate?
- What explains the drop in cash from $169.6M to $90.8M and the negative FY 2025 free cash flow of $-22.5M?
- What is the source and composition of the FY 2023 debt figure of $1847.4M, which is far above later periods?
- What is the identity and size of the institutional holders and the insider selling referenced in the news wire, since the holders section is empty?
GKOS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Glaukos Corporation (GKOS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 12h ago
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? Yahoo Finance report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 15h ago
Glaukos stock slips after insider selling (GKOS:NYSE) Seeking Alpha report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 18h ago
Glaukos Corporation Stock 12‑Month Price Target Raised to $235.46, Implies 30% Upside TradingView report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 21h ago
Glaukos (NYSE:GKOS) Stock Forecast & Analyst Predictions Simply Wall St report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A live webcast on Glaukos's third-quarter results is set for Oct. 28 at 1:30 p.m. PT. Stock Titan report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Earnings Flash (GKOS) Glaukos Corporation Posts Q3 Adjusted EPS $0.47 per Share, vs. FactSet Est of $-0.10 marketscreener.com report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Kalkine • 1d ago
Top 5 Stocks for October 29 Pre-Market: Earnings Reaction Gainers Led by Glaukos Corporation (NYSE:GKOS) at 15.75% Kalkine report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Why Glaukos (GKOS) Stock Is Up Today Quiver Quantitative report covering Glaukos Corporation (GKOS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GKOS Bull vs. Bear Conversation Board — What's Your Call at $237.60?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GKOS 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $261.88 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is GKOS (D+ • RQD 58/100) a Buy at $242.48?
Welcome to the GKOS (Glaukos Corporation) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $198.83 (-18.0%)
Spot @ $242.48 Pump the brakes on GKOS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GKOS, but look at what you are paying: current EV/EBITDA multiples with 55.7% gross margins. Unless Glaukos Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $305.52 (+26.0%)
Spot @ $242.48 GKOS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GKOS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $242.48 (52-wk range $80.90 - $248.75), any beat on forward guidance forces shorts and underweight funds to chase.